We are live on ! Find out more
FATE icon

Fate Therapeutics
FATE

60 hedge funds and large institutions have $86.2M invested in Fate Therapeutics in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 14

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

13% more funds holding

Funds holding: 53 → 60 (+7)

3.81% more ownership

Funds ownership: 60.47% → 64.28% (+3.8%)

24% less capital invested

Capital invested by funds: $114M → $86.2M (-$27.7M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
60
Holders Change
+7
Holders Change %
+13.21%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
21
Increased
16
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.02M
2
CC
Casdin Capital
New York
+$2.11M
3
State Street
State Street
Massachusetts
+$1.7M
4
Northern Trust
Northern Trust
Illinois
+$1.28M
5
6CM
683 Capital Management
New York
+$453K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$5.95M
2
KCM
Kingdon Capital Management
New York
-$2.15M
3
Millennium Management
Millennium Management
New York
-$545K
4
SCM
Segantii Capital Management
Hong Kong
-$182K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$173K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$19.7M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$14.1M -$173K -45,100 -1%
EC
3
EcoR1 Capital
California
$8.22M – – –
PVMCV
4
Polaris Venture Management Co V
Massachusetts
$8.01M – – –
BlackRock
5
BlackRock
New York
$5.38M +$6.02M +1,572,438 +1,822%
RG
6
Redmile Group
California
$4.6M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.1M +$416K +108,602 +9%
KCM
8
Kingdon Capital Management
New York
$3.73M -$2.15M -561,011 -33%
Morgan Stanley
9
Morgan Stanley
New York
$2.05M +$85.4K +22,298 +4%
6CM
10
683 Capital Management
New York
$1.91M +$453K +118,237 +25%
CC
11
Casdin Capital
New York
$1.78M +$2.11M +550,000 New
State Street
12
State Street
Massachusetts
$1.44M +$1.7M +443,462 New
BI
13
BVF Inc
California
$1.27M -$5.95M -1,553,859 -80%
Northern Trust
14
Northern Trust
Illinois
$1.19M +$1.28M +333,753 +969%
Renaissance Technologies
15
Renaissance Technologies
New York
$1M +$50.2K +13,100 +4%
Wells Fargo
16
Wells Fargo
California
$820K -$107K -28,048 -10%
BCM
17
Bridgeway Capital Management
Texas
$810K – – –
TI
18
Telemetry Investments
New York
$731K +$290K +75,700 +50%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$573K +$221K +57,568 +48%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$511K +$376K +98,036 +165%
TCIM
21
TIAA CREF Investment Management
New York
$373K +$442K +115,275 New
Goldman Sachs
22
Goldman Sachs
New York
$362K -$124K -32,278 -22%
AG
23
Algert Global
California
$331K +$391K +102,169 New
OAM
24
Oxford Asset Management
United Kingdom
$303K +$359K +93,583 New
TA
25
Teachers Advisors
New York
$233K +$276K +71,990 New
1
2 3

FATE Hedge Fund Activity: Q2 2017 in Review

60 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2017, worth a combined $86.2M — down 24% from $114M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new FATE positions and 14 closed out — a net gain of 7 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $6.02M. The largest seller was BVF Inc, cutting an estimated $5.95M.

  • 60 institutional investors held Fate Therapeutics (FATE) as of Q2 2017, up from 53 in Q1 2017.
  • Funds reported $86.2M of Fate Therapeutics stock for Q2 2017, down 24% quarter-over-quarter.
  • 21 funds opened new Fate Therapeutics positions in Q2 2017 and 14 closed out, a net change of +7 holders.
  • The largest Fate Therapeutics buyer in Q2 2017 was BlackRock, an estimated $6.02M added.
  • The largest Fate Therapeutics seller in Q2 2017 was BVF Inc, an estimated $5.95M sold.

Based on aggregated 13F filings for Q2 2017.